Department of Epidemiology and Biostatistics

Our Amazing Team
From Top to Bottom: Ryan, Aanchal,Tiffany, Maia, Dr. Meghan Morris, Claire, Irwin, Neia
TEAM BIOs
YETI Team
This study aims to increase hepatitis C treatment initiation among young adults who inject drugs
YETI Study
NOW Study Team
Working alongside community members for the NOW study site.
NOW Study site team
Working with community site partners
NOW Study Participant
The study will evaluate the feasibility and acceptability of an accelerated treatment program for chronic HCV diagnosis.
NOW Study
SF Build: Building Bridges Scholars
SF Build Aims to create an intellectually safe and affirming environment at partnering institutions where minority students can thrive and become scientists.
SFBuild

About Dr. Meghan Morris

Meghan D. Morris's mission is to utilize epidemiological methods to investigate the impact of individual, social, and structural factors on disease transmission, particularly within drug-using populations. Her research focuses on HIV and hepatitis C virus (HCV) infection worldwide, with an emphasis on people who inject drugs (PWID). Collaborating internationally, she has contributed to HIV and HCV prevention studies in various regions. As the head of the End HepC SF research workgroup, Morris leads research projects to estimate disease burden and evaluate public health interventions. Her expertise extends to dyadic research methods, exploring interpersonal factors influencing disease transmission and medical engagement. Furthermore, she aims to create community-engaged research through initiatives like the Research Enhancing and Advancing Community Health (REACH) program, aiming to reduce health disparities and foster diversity in STEM workforce pathways.